Xencor, Inc. (NASDAQ:XNCR) Receives Average Rating of "Moderate Buy" from Analysts

Xencor, Inc. (NASDAQ:XNCR - Get Free Report) has been given an average recommendation of "Moderate Buy" by the nine brokerages that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, seven have given a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $29.50.

Several equities analysts have recently weighed in on XNCR shares. Barclays decreased their price target on shares of Xencor from $22.00 to $6.00 and set an "underweight" rating on the stock in a research note on Thursday, May 8th. Wells Fargo & Company decreased their price target on shares of Xencor from $37.00 to $33.00 and set an "overweight" rating on the stock in a research note on Friday, February 28th. Wall Street Zen downgraded shares of Xencor from a "hold" rating to a "sell" rating in a research note on Friday, March 14th. Wedbush reissued an "outperform" rating and issued a $31.00 price target on shares of Xencor in a research note on Wednesday, April 30th. Finally, William Blair began coverage on shares of Xencor in a research note on Monday, April 21st. They issued an "outperform" rating on the stock.

Xencor Price Performance

Shares of NASDAQ XNCR traded down $0.22 during trading on Friday, hitting $9.52. The company had a trading volume of 482,548 shares, compared to its average volume of 667,272. The stock has a fifty day simple moving average of $9.01 and a two-hundred day simple moving average of $15.41. Xencor has a fifty-two week low of $7.16 and a fifty-two week high of $27.24. The firm has a market capitalization of $677.55 million, a price-to-earnings ratio of -2.98 and a beta of 0.87. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.01.

Xencor (NASDAQ:XNCR - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.06). The business had revenue of $32.73 million during the quarter, compared to analysts' expectations of $23.44 million. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The business's quarterly revenue was up 104.6% on a year-over-year basis. During the same period in the prior year, the business posted ($1.11) earnings per share. On average, research analysts expect that Xencor will post -3.68 earnings per share for the current year.

Insiders Place Their Bets

In other news, EVP Nancy Valente sold 4,616 shares of the business's stock in a transaction that occurred on Friday, May 2nd. The shares were sold at an average price of $11.03, for a total value of $50,914.48. Following the sale, the executive vice president now directly owns 49,169 shares of the company's stock, valued at approximately $542,334.07. The trade was a 8.58% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.76% of the stock is owned by insiders.

Institutional Investors Weigh In On Xencor

A number of institutional investors and hedge funds have recently made changes to their positions in XNCR. RTW Investments LP raised its stake in shares of Xencor by 317.9% in the 4th quarter. RTW Investments LP now owns 2,402,883 shares of the biopharmaceutical company's stock valued at $55,218,000 after acquiring an additional 1,827,883 shares during the period. BVF Inc. IL raised its stake in shares of Xencor by 169.3% in the 4th quarter. BVF Inc. IL now owns 2,288,760 shares of the biopharmaceutical company's stock valued at $52,596,000 after acquiring an additional 1,438,760 shares during the period. Braidwell LP raised its stake in shares of Xencor by 169.0% in the 1st quarter. Braidwell LP now owns 1,655,690 shares of the biopharmaceutical company's stock valued at $17,617,000 after acquiring an additional 1,040,159 shares during the period. Primecap Management Co. CA raised its stake in shares of Xencor by 8.6% in the 1st quarter. Primecap Management Co. CA now owns 9,761,012 shares of the biopharmaceutical company's stock valued at $103,857,000 after acquiring an additional 776,580 shares during the period. Finally, Nuveen Asset Management LLC raised its stake in shares of Xencor by 452.4% in the 4th quarter. Nuveen Asset Management LLC now owns 837,082 shares of the biopharmaceutical company's stock valued at $19,236,000 after acquiring an additional 685,557 shares during the period.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.